Pulmozyme Efficacy & Tolerability: Rate of CF Exacerbations

Pulmozyme provided additional treatment benefits by reducing exacerbation* risk

Pulmozyme reduced the risk of exacerbations* among patients >5 years of age with FVC >40% of predicted1

exacerbation

*Requiring parenteral antibiotics † All patients also received standard therapies for cystic fibrosis + OD = Once daily

 

 

Young patients with early disease also benefitted from Pulmozyme in a 2-year clinical trial

Pulmozyme reduced the risk of exacerbations* among patients in patients with FVC ≥85% predicted, aged 6 to 10 years

*Requiring parenteral antibiotics † All patients also received standard therapies for cystic fibrosis + OD = Once daily

1. Pulmozyme SmPC, Electronic Medicines Compendium, accessed 10/8/18

25. Fuchs HJ et al. Effect of aerosolized recombinant humsn Dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-642.

26. Quam JM et al. A two-year randomized. Placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001;139(6):813-820.